ITRM Stock Overview
A pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Iterum Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.02 |
| 52 Week High | US$3.02 |
| 52 Week Low | US$0.81 |
| Beta | 2.91 |
| 1 Month Change | -8.11% |
| 3 Month Change | -26.62% |
| 1 Year Change | -34.19% |
| 3 Year Change | -68.89% |
| 5 Year Change | -98.02% |
| Change since IPO | -99.47% |
Recent News & Updates
Recent updates
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
Aug 19
Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03
Aug 12Iterum jumps 64% as FDA agrees to Phase 3 trial for UTI candidate
Jul 11Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
May 06Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
Jan 12Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?
Sep 25Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy
Jul 05It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year
Jun 11Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?
May 20Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?
Feb 04This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)
Feb 04Shareholder Returns
| ITRM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.3% | -6.8% | -0.3% |
| 1Y | -34.2% | -9.8% | 8.1% |
Return vs Industry: ITRM underperformed the US Pharmaceuticals industry which returned -9.8% over the past year.
Return vs Market: ITRM underperformed the US Market which returned 8.1% over the past year.
Price Volatility
| ITRM volatility | |
|---|---|
| ITRM Average Weekly Movement | 12.3% |
| Pharmaceuticals Industry Average Movement | 10.9% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: ITRM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ITRM's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 9 | Corey Fishman | www.iterumtx.com |
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases.
Iterum Therapeutics plc Fundamentals Summary
| ITRM fundamental statistics | |
|---|---|
| Market cap | US$35.27m |
| Earnings (TTM) | -US$24.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs ITRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ITRM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$254.00k |
| Gross Profit | -US$254.00k |
| Other Expenses | US$24.52m |
| Earnings | -US$24.77m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 13, 2025
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -1,115.8% |
How did ITRM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 12:09 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Iterum Therapeutics plc is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adnan Butt | Guggenheim Securities, LLC |
| Antonio Arce | H.C. Wainwright & Co. |
| Matthew Keller | H.C. Wainwright & Co. |